Friends at a restaurant enjoying a pizza
A neon sign saying - Turn the tables on EoE.

EOHILIA. Designed for EoE.
Dedicated to relief.*

*Relief is defined as a decrease in eosinophils (a type of white blood cell) in the esophagus and improvement in dysphagia (difficulty swallowing), as demonstrated by EOHILIA in two 12-week clinical trials.

What is EOHILIA?

It is the first and only 12-week, FDA-approved oral treatment for EoE in people 11 years and older.

EOHILIA™ (budesonide oral suspension) box and single-dose packaging
Image of a couple having a meal

Why EOHILIA?

EOHILIA has been proven to treat EoE inflammation in the esophagus, as demonstrated in two clinical trials.†

In two clinical trials, EOHILIA showed a decrease in eosinophils (a type of white blood cell) in the esophagus and improvement in dysphagia (difficulty swallowing).

The EOHILIA Patient Support and Copay Program

The EOHILIA Patient Support and Copay Program is designed to support eligible commercially insured patients on their treatment journey. Sign up below to receive a digital copay card and updates about EOHILIA delivered straight to your inbox.

Commercially insured patients prescribed EOHILIA may receive a one-time 30-day supply at no cost if access is not initially granted by your insurance provider.

Read the EOHILIA Terms and Conditions here.

Example of the EOHILIA™ digital copay card
You may be able to pay as little as $0 for EOHILIA.